These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33754407)

  • 41. CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.
    Gnjatic S; Jäger E; Chen W; Altorki NK; Matsuo M; Lee SY; Chen Q; Nagata Y; Atanackovic D; Chen YT; Ritter G; Cebon J; Knuth A; Old LJ
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11813-8. PubMed ID: 12186971
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.
    Neumann F; Kubuschok B; Ertan K; Schormann C; Stevanovic S; Preuss KD; Schmidt W; Pfreundschuh M
    Cancer Immunol Immunother; 2011 Sep; 60(9):1333-46. PubMed ID: 21630107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peptides of tetraspanin oncoprotein CD151 trigger active immunity against primary tumour and experimental lung metastasis.
    Lin W; Liu J; Chen J; Li J; Qiu S; Ma J; Lin X; Zhang L; Wu J
    EBioMedicine; 2019 Nov; 49():133-144. PubMed ID: 31668880
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
    Xu M; Kallinteris NL; von Hofe E
    Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.
    Gannon PO; Wieckowski S; Baumgaertner P; Hebeisen M; Allard M; Speiser DE; Rufer N
    J Immunol; 2015 Jul; 195(1):356-66. PubMed ID: 26002978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.
    Liu C; Chu X; Sun P; Feng X; Huang W; Liu H; Ma Y
    Hum Vaccin Immunother; 2018 Apr; 14(4):931-940. PubMed ID: 29271696
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemical Strategies to Boost Cancer Vaccines.
    Li WH; Li YM
    Chem Rev; 2020 Oct; 120(20):11420-11478. PubMed ID: 32914967
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination therapies utilizing neoepitope-targeted vaccines.
    Lee KL; Schlom J; Hamilton DH
    Cancer Immunol Immunother; 2021 Apr; 70(4):875-885. PubMed ID: 33033852
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors.
    Jalali SA; Parmiani G
    Recent Pat Biotechnol; 2011 Aug; 5(2):108-17. PubMed ID: 21707528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
    Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
    Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
    Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
    J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.
    Haug M; Brede G; Håkerud M; Nedberg AG; Gederaas OA; Flo TH; Edwards VT; Selbo PK; Høgset A; Halaas Ø
    Front Immunol; 2018; 9():650. PubMed ID: 29670624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
    Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
    Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peptide-Based Treatment: A Promising Cancer Therapy.
    Xiao YF; Jie MM; Li BS; Hu CJ; Xie R; Tang B; Yang SM
    J Immunol Res; 2015; 2015():761820. PubMed ID: 26568964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peptides for Vaccine Development.
    Hamley IW
    ACS Appl Bio Mater; 2022 Mar; 5(3):905-944. PubMed ID: 35195008
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
    Iero M; Filipazzi P; Castelli C; Belli F; Valdagni R; Parmiani G; Patuzzo R; Santinami M; Rivoltini L
    Cancer Immunol Immunother; 2009 Jul; 58(7):1159-67. PubMed ID: 18998128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.